Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

9.760 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 444,626
Open 9.760
Bid (Size) 9.200 (5,400)
Ask (Size) 9.250 (2,300)
Prev. Close 9.760
Today's Range 9.760 - 9.760
52wk Range 2.745 - 10.29
Shares Outstanding 287,686,199
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From AbCellera Biologics Inc.
Via Business Wire
Here are the top movers in Monday's session. ↗
Via Chartmill

Performance

YTD
+184.5%
+184.5%
1 Month
+49.7%
+49.7%
3 Month
+97.2%
+97.2%
6 Month
+208.9%
+208.9%
1 Year
+116.9%
+116.9%

More News

Read More
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
AI Found an Influenza Target That Survives Viral Mutation
From Equity Insider
Via GlobeNewswire
AbCellera Biologics (NASDAQ:ABCL) Misses Q2 Estimates, Falls Short on Revenue and EPS ↗
Via Chartmill
News headline image
AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial ↗
Via MarketBeat
News headline image
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
From AbCellera Biologics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Biologics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
AbCellera Reports Q2 2026 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam ↗
Via MarketBeat
News headline image
AbCellera Biologics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
AbCellera (ABCL) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Intellectual Property
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
From AbCellera Biologics Inc.
Via Business Wire

Frequently Asked Questions

Is AbCellera Biologics Inc. - Common Shares publicly traded?
Yes, AbCellera Biologics Inc. - Common Shares is publicly traded.
What exchange does AbCellera Biologics Inc. - Common Shares trade on?
AbCellera Biologics Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AbCellera Biologics Inc. - Common Shares?
The ticker symbol for AbCellera Biologics Inc. - Common Shares is ABCL on the Nasdaq Stock Market
What is the current price of AbCellera Biologics Inc. - Common Shares?
The current price of AbCellera Biologics Inc. - Common Shares is 9.760
When was AbCellera Biologics Inc. - Common Shares last traded?
The last trade of AbCellera Biologics Inc. - Common Shares was at 08/11/26 04:00 PM ET
What is the market capitalization of AbCellera Biologics Inc. - Common Shares?
The market capitalization of AbCellera Biologics Inc. - Common Shares is 2.81B
How many shares of AbCellera Biologics Inc. - Common Shares are outstanding?
AbCellera Biologics Inc. - Common Shares has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.